Mobile App for Improving Adherence of Rivoxaban (RIVOX-AF)
NCT ID: NCT05557123
Last Updated: 2025-01-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
1042 participants
INTERVENTIONAL
2022-03-10
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
APIXABAN App Study
NCT06903845
Shared Decision-Making: AFib 2gether Mobile App
NCT04118270
Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban
NCT02549963
A Fib Clinic of the Future Using KardiaPro Platform for Chronic Care of Patients With AF After Ablation Procedure
NCT03557034
An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation
NCT05565599
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MEDI-app
conventional treatment with MEDI-app feedback
MEDI-app
MEDI-app based feedback algorithm. The app based feedback algorithm will check and remind the patients of taking medication.
conventional treatment
conventional treatment
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MEDI-app
MEDI-app based feedback algorithm. The app based feedback algorithm will check and remind the patients of taking medication.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients who already took or plan to take rivoxban
* patients who able to use smart phone
Exclusion Criteria
* moderate or severe mitral stenosis
* mitral valve operation history
* current alcohol abuse or alcohol abus history
* Not eligible for study due to legal or psychiatric problem
* enrolled other clinical study within 4 weeks
* declined to enroll the study
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SAMJIN PHARM
UNKNOWN
Seoul National University Bundang Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dong-Ju Choi
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dong-Ju Choi, MD, PhD
Role: STUDY_CHAIR
Seoul National Univeristy Bundang Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Bundang Hospital
Seongnam, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Yoon M, Park JJ, Hur T, Hua CH, Shim CY, Yoo BS, Cho HJ, Lee S, Kim HM, Kim JH, Lee S, Choi DJ. The ReInforcement of adherence via self-monitoring app orchestrating biosignals and medication of RivaroXaban in patients with atrial fibrillation and co-morbidities: a study protocol for a randomized controlled trial (RIVOX-AF). Front Cardiovasc Med. 2023 May 24;10:1130216. doi: 10.3389/fcvm.2023.1130216. eCollection 2023.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RIVOX-AF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.